MedPacto, Inc. (KOSDAQ:235980)

South Korea flag South Korea · Delayed Price · Currency is KRW
7,510.00
-350.00 (-4.45%)
Nov 20, 2025, 3:30 PM KST
-4.45%
Market Cap269.40B
Revenue (ttm)2.47B
Net Income (ttm)-14.57B
Shares Out34.28M
EPS (ttm)-426.06
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,446,132
Average Volume1,808,290
Open7,770.00
Previous Close7,860.00
Day's Range7,420.00 - 8,040.00
52-Week Range2,750.00 - 8,650.00
Beta0.69
RSI83.21
Earnings DateNov 11, 2025

About MedPacto

MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Seong-Jin Kim
Employees 56
Stock Exchange KOSDAQ
Ticker Symbol 235980
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.